TransEnterix (NYSE:TRXC) said today it signed an distribution deal with Getz Healthcare for its Senhance surgical robotics system.
The deal will position Getz Healthcare as the exclusive distributor of the Senhance system in the Australian and New Zealand markets, according to Morrisville, N.C.-based TransEnterix.
“Australia and New Zealand are key markets in the healthcare industry, with leading hospitals and a growing interest in robotic surgery. Getz Healthcare is an integrated healthcare distributor with a long track record of success in selling and supporting hospital products. We are excited to partner with such a talented and experienced team in this important region,” TransEnterix prez & CEO Todd Pope said in a press release.
“The Senhance will now be a leading product for our medical device business in Australia and New Zealand. We chose to partner with TransEnterix because of the tremendous value proposition that the Senhance provides to patients and healthcare providers. Hospitals today are seeking a new way to utilize robotics in surgery that allows them to better manage operational costs. The Senhance’s unique features, including haptic force feedback and eye sensing camera control, as well as its attractive economics are providing surgeons an improved solution,” Getz Healthcare CEO James Simkins said in a perpared statement.
In September, TransEnterix rebranded its ALF-X robotic surgical system as the Senhance surgical robotic system. The company said it made the switch to the new name and logo, which features a thumb-print combined with circuity, as a representation of the connection between surgeon and technology that the robotic system provides.
The company acquired the Telelap ALF-X robot-assisted surgery device from Italy’s Sofar SpA last September. The Telelap ALF-X device has CE Mark approval in the European Union for minimally invasive surgery procedures.
The Morrisville, N.C.-based company sold its 1st ALF-X system in August to Milan, Italy’s Humanitas Hospital.
TransEnterix shelved its SurgiBot robot-assisted surgery device earlier this year after the FDA denied its submission for 510(k) clearance for the SurgiBot, which it claims as the 1st patient-side robotically enhanced laparoscopy platform designed to be wheeled to a patient’s bedside for single-port procedures.
